Cytokeratin7 antibody human specific - HS-454 017

Cytokertain 7 is a type II keratin specifically expressed in the simple epithelia lining the cavities of the internal organs and in the gland ducts and blood vessels
Rat monoclonal purified IgG
Cat. No.: HS-454 017
Amount: 200 µl
Price: $415.00
Cat. No. HS-454 017 200 µl purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 200 µl H2O. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
WB: 1 : 1000 gallery  
IP: not tested yet
ICC: 1 : 100 gallery  
IHC: not tested yet
IHC-P: 1 : 100 gallery  
Clone 123E11H11
Subtype IgG2a (κ light chain)
Immunogen Synthetic peptide corresponding to residues surrounding AA 450 of human CK7 (UniProt Id: P08729)
Reactivity Reacts with: human (P08729).
No signal: mouse (Q9DCV7).
Other species not tested yet.
Data sheet hs-454_017.pdf
Cat. No.: HS-454 017
Amount: 200 µl
Price: $415.00

Cytokeratin 7 staining in a human CK7-positive pancreatic adenocarcinoma (A) and a human CK7-negative colon carcinoma xenograft (B)


Cytokeratins are cytoskeleton proteins of epithelial tissues, contributing to the mechanical stabilization of the cells. The cytokeratin family consists of at least 20 isotypes, which are largely specific for particular organs or tissue types. Therefore, immunohistochemical staining of cytokeratins is clinically used for diagnosis of carcinomas, in particular of unclear metastases and in precise classification and subtyping of tumors (1). Cytokeratin 7 (CK7) is expressed in healthy bladder, in the female genital tract epithelium, in mesothelium and in the lung (2). In tumors, CK7 expression is found in the majority of carcinoma types, with the exception of those carcinomas arising from the colon, prostate, kidney and thymus (3). Furthermore, CK7 expression can have prognostic relevance, e.g. adverse prognostic factor in lung cancer (4), or predictive relevance, e.g. predictive factor of response to concurrent radiochemotherapy in advanced cervical cancer (5).

Protocols for HS-454 017